Cases & Deals

Share

Pfizer acquires Serenex, Inc

December 2007

Client(s) Pfizer, Inc.

Jones Day acted as tax counsel to Pfizer, Inc. in its acquisition of Serenex, Inc., a privately-held biotechnology company. As per the agreement, Pfizer acquired the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase 1 trials for the potential treatments of tumors and hematological malignancies.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.